{"title":"非小细胞肺癌放射治疗生存预后预测的放射学特征的鉴定和验证","authors":"Jin Li, Yixin Liu, Jingquan Wu","doi":"10.1109/ICMLA52953.2021.00095","DOIUrl":null,"url":null,"abstract":"Radiomics is a novel tool which extracts quantitative features from medical imaging, and combines key features into an image-based radiomic signature for cancer diagnostics. We aimed to develop a quantitative radiomic signature for predicting survival outcomes in non-small-cell lung cancer (NSCLC) patients treated with radiation therapy. Based on computed tomography (CT) imaging of NSCLC, we applied a forward selection procedure for the establishment of a radiomic signature in a cohort with 107 NSCLC patients treated with radiation therapy, and validated it in a dataset with 88 patients. The radiomics signatures were significantly associated with NSCLC patients’ survival time. In a Testing dataset, the predicted high risk patients had significantly shorter overall survival than the predicted low risk patients (log-rank $P=$ 0.0004, HR $=$ 2.75, 95% CIs: 1.58–4.80, C-index $=$ 0.64). Further, the novel proposed radiomic nomogram combining the radiomic signature and clinicopathological factors improved the prognostic performance. The CT-based radiomic signature exhibited a good performance for noninvasively identifying patients with NSCLC who should receive postoperative radiation therapy. These results provide a more precise reference for the accurate diagnosis and treatment of NSCLC in clinical.","PeriodicalId":6750,"journal":{"name":"2021 20th IEEE International Conference on Machine Learning and Applications (ICMLA)","volume":"2 1","pages":"570-574"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Identification and validation of a radiomic signature for predicting survival outcomes in non-small-cell lung cancer treated with radiation therapy\",\"authors\":\"Jin Li, Yixin Liu, Jingquan Wu\",\"doi\":\"10.1109/ICMLA52953.2021.00095\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Radiomics is a novel tool which extracts quantitative features from medical imaging, and combines key features into an image-based radiomic signature for cancer diagnostics. We aimed to develop a quantitative radiomic signature for predicting survival outcomes in non-small-cell lung cancer (NSCLC) patients treated with radiation therapy. Based on computed tomography (CT) imaging of NSCLC, we applied a forward selection procedure for the establishment of a radiomic signature in a cohort with 107 NSCLC patients treated with radiation therapy, and validated it in a dataset with 88 patients. The radiomics signatures were significantly associated with NSCLC patients’ survival time. In a Testing dataset, the predicted high risk patients had significantly shorter overall survival than the predicted low risk patients (log-rank $P=$ 0.0004, HR $=$ 2.75, 95% CIs: 1.58–4.80, C-index $=$ 0.64). Further, the novel proposed radiomic nomogram combining the radiomic signature and clinicopathological factors improved the prognostic performance. The CT-based radiomic signature exhibited a good performance for noninvasively identifying patients with NSCLC who should receive postoperative radiation therapy. These results provide a more precise reference for the accurate diagnosis and treatment of NSCLC in clinical.\",\"PeriodicalId\":6750,\"journal\":{\"name\":\"2021 20th IEEE International Conference on Machine Learning and Applications (ICMLA)\",\"volume\":\"2 1\",\"pages\":\"570-574\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"2021 20th IEEE International Conference on Machine Learning and Applications (ICMLA)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1109/ICMLA52953.2021.00095\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"2021 20th IEEE International Conference on Machine Learning and Applications (ICMLA)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1109/ICMLA52953.2021.00095","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Identification and validation of a radiomic signature for predicting survival outcomes in non-small-cell lung cancer treated with radiation therapy
Radiomics is a novel tool which extracts quantitative features from medical imaging, and combines key features into an image-based radiomic signature for cancer diagnostics. We aimed to develop a quantitative radiomic signature for predicting survival outcomes in non-small-cell lung cancer (NSCLC) patients treated with radiation therapy. Based on computed tomography (CT) imaging of NSCLC, we applied a forward selection procedure for the establishment of a radiomic signature in a cohort with 107 NSCLC patients treated with radiation therapy, and validated it in a dataset with 88 patients. The radiomics signatures were significantly associated with NSCLC patients’ survival time. In a Testing dataset, the predicted high risk patients had significantly shorter overall survival than the predicted low risk patients (log-rank $P=$ 0.0004, HR $=$ 2.75, 95% CIs: 1.58–4.80, C-index $=$ 0.64). Further, the novel proposed radiomic nomogram combining the radiomic signature and clinicopathological factors improved the prognostic performance. The CT-based radiomic signature exhibited a good performance for noninvasively identifying patients with NSCLC who should receive postoperative radiation therapy. These results provide a more precise reference for the accurate diagnosis and treatment of NSCLC in clinical.